RECITE Trial: Romiplostim Prevents Chemotherapy Side Effects and Preserves Treatment Intensity

PSMA PET/CT May Transform Prostate Cancer Diagnosis and Reduce Biopsies by 50%

Designing Digital Healthcare Systems for the Future of Patient-Centered Care

Amivantamab Plus Chemotherapy Shows Promising Long-Term Responses in Colorectal Cancer

Novartis Expands US Radioligand Manufacturing With $23 Billion Investment in Florida

Rewiring RNA: Antisense RNA Therapy Exposes a New Weakness in Pancreatic Cancer

FDA Approves First Subcutaneous Amivantamab Plus Lazertinib for EGFR+ Lung Cancer

Platinum-Free PADCEV Plus Pembrolizumab Improves Survival in MI Bladder Cancer

FDA Approves T-DXd Plus Pertuzumab as a First-Line Standard in HER2+ Breast Cancer

Teclistamab plus Daratumumab Achieves an 83% Risk Reduction in R/R Multiple Myeloma

FDA Approves AKEEGA for BRCA2+ Prostate Cancer as the First Precision Therapy

GSK’s ADC Risvutatug Rezetecan Earns FDA Orphan Drug Status for Small Cell Lung Cancer

Ribociclib Maintains Long-Term Disease Control in HR+ HER2 Metastatic Breast Cancer

Preoperative Radiation May Improve Immune Response in HR+ HER2- Breast Cancer

Tucatinib Combination Cuts Progression Risk by 36% in HER2+ Metastatic Breast Cancer

Giredestrant Cuts Risk of Invasive Recurrence by 30% in Early ER+ Breast Cancer

CAR T Anito cel Delivers Deep, Durable Responses in R&R Multiple Myeloma

Lunsumio Combo Deliver High Response Rates in Follicular and Large B-Cell Lymphomas

Lung Organoids Offer a Revolutionary Path to Transform Drug Testing and Cancer Therapies

Enozertinib Shows Strong Systemic and CNS Activity in EGFR Exon 20+ NSC Lung Cancer

Colibactin’s Molecular Blueprint Exposes How a Gut Microbial Toxin Triggers Colorectal Cancer

Blood-Based cfDNA Test Demonstrates Potential for Detecting Lung Cancer in Nonsmokers

FDA Approves Durvalumab as First Perioperative Immunotherapy for GEJ Cancers

FDA Approves Keytruda–Padcev Combo as First Perioperative Treatment for Bladder Cancer

Sevabertinib Wins FDA Approval with Strong Responses in HER2+ NSC Lung Cancer

FDA Approves Epcoritamab-bysp as the First Bispecific Antibody for Follicular Lymphoma

FDA Approves Ziftomenib as a New Targeted Option for NPM1+ Acute Myeloid Leukemia

Radioligand Therapy Pluvicto Reduces Progression Risk by 28% in mHS Prostate Cancer

Lenvatinib Plus Everolimus Improves Outcomes After PD-1 Failure in Kidney Cancer

Novartis Invests $23 Billion to Boost Radioligand Manufacturing Capacity in Carlsbad

Ribociclib Extends Disease-Free Survival Beyond Treatment in HR+/HER2– Early Breast Cancer

DeLLphi-303: Tarlatamab Plus Chemo Achieves 71% Response in ES Small-Cell Lung Cancer

ctDNA Blood Test Guides Chemotherapy Decisions for Tailored Colon Cancer Treatment

Trodelvy Emerges as Potential New Standard for First-Line Metastatic TN Breast Cancer

Datroway Extends Survival by 5 Months in Metastatic Triple-Negative Breast Cancer

Lenvatinib Plus Pembrolizumab Delivers Durable 5-Year Survival in Endometrial Carcinoma

Reprogramming Cancer Cell Death: A New Immune-Based Strategy for Blood Cancers

In Vivo CAR T on the Horizon: BMS Acquires Orbital to Expand Cell Therapy Reach

AstraZeneca makes deal with Trump Admin to Cut Drug Prices 80% and Invest $50B in US

FDA Approves Libtayo as First Adjuvant Immunotherapy for High-Risk CS Cell Carcinoma

Datroway Improves Survival in First-Line Treatment of Metastatic Triple- Breast Cancer

FDA Approves Tecentriq–Zepzelca Combo as FL Maintenance Therapy for ES-SC Lung Cancer

FDA Approves Imlunestrant for ESR1-Mutated Metastatic Breast Cancer

DESTINY-Breast05: Enhertu Outperforms T-DM1 in High-Risk HER2+ Early Breast Cancer

Giredestrant Plus Everolimus Improves PF Survival in ER+ Advanced Breast Cancer

EMA’s CHMP Backs Subcutaneous Pembrolizumab in Head and Neck Cancer

FDA Grants Breakthrough Status to Raludotatug Deruxtecan for Refractory Ovarian Cancer

GSK to invest $30 billion in R&D and Manufacturing in the US over next 5 years

Climate-Driven Health Risks to Put $1.5 Trillion in Productivity at Stake by 2050

CVC and V Foundation Fuel $500K Grant for Next Phase of Breast Cancer Vaccine Research